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Available online xxxxThe mucopolysaccharidoses (MPS disorders) are rare inherited diseases associated with multi-organ accumula-
tion of glycosaminoglycans, leading tomusculoskeletal, respiratory, cardiac, neurological, ophthalmological, oto-
laryngological, and gastrointestinal abnormalities. As a result of improvements in diagnosis, multi-disciplinary
care, and therapies such as enzyme replacement therapy andhematopoietic stemcell transplantation, an increas-
ing number of patientswithMPS are reaching adulthood and are involved in family planning. Data on fertility and
pregnancy outcome inMPS is sparse and comprises primarily isolated case reports. To address this evidence gap,
we present a case series on fertility and pregnancy in eight mothers and five fathers with MPS. This case series
demonstrates thatwomenwithMPS have high-risk pregnancies anddeliveries secondary to their underlying dis-
ease. However, with appropriate pre-conceptual multi-disciplinary evaluation, optimization and discussion re-
garding potential risks, combined with regular multi-disciplinary maternal and fetal surveillance in a tertiary
center, the outcome of most pregnancies in this case series seems to be favorable with all babies developing nor-
mally. Partners of fathers with MPS had uncomplicated pregnancies and deliveries. All children were healthy,
with normal growth and development.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Elosulfase alfa
Enzyme replacement therapy
Mucopolysaccharidoses
Pregnancy1. Introduction
The mucopolysaccharidoses (MPS disorders) are rare inherited lyso-
somal storage diseases caused by deficiencies in enzymes involved in gly-
cosaminoglycan (GAG) catabolism. The resulting accumulation ofGAGs in
tissues and organs leads to skeletal and joint abnormalities (hip dysplasia,
knee or ankle valgus, kyphosis, scoliosis, atlanto-axial instability, chest de-
formities, joint stiffness/hypermobility), cardiopulmonary compromise
(upper/lower airway obstruction, restrictive lung disease, cardiac valveAG, glycosaminoglycan; HSCT,
accharidosis.
l Genetics Centre, Belfast City
nd, UK.
F.J. Stewart).
. This is an open access article underdisease, left ventricular hypertrophy), neurological problems secondary
to spinal cord compression, hepatosplenomegaly, and impaired vision
and hearing [1]. Cognitive decline occurs in severe forms ofMPS I (mainly
Hurler [MPS IH], Hurler-Scheie [MPS IHS] syndrome),MPS II (Hunter syn-
drome), MPS III (Sanfilippo syndrome) and MPS VII (Sly syndrome) [1].
There is wide genotypic and phenotypic heterogeneity among the MPS
types. All are autosomal recessive disorders, except MPS II which is X-
chromosome linked and typically occurs in males [1].
Recent improvements in diagnosis, multi-disciplinary care, and
treatments such as enzyme replacement therapy (ERT) and hematopoi-
etic stem cell transplantation (HSCT) have led to increased life expec-
tancy and a growing number of adult MPS patients. Not surprisingly,
MPS adults are considering starting families or are actively pursuing
having children. While case reports describing fertility and pregnancy
in women with MPS are rare [2–10], even less data exists on fathersthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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can be problematic in women with MPS [2–5,8]. Small stature,
obstructive and restrictive respiratory disease, cardiac issues (mostly
valve disease), spinal cord compression, hepatosplenomegaly, andmus-
culoskeletal abnormalities might interfere with normal pregnancy and
delivery or exacerbate due to pregnancy [11–18]. Use of steroids (as
pre-treatment with ERT to avoid infusion-associated reactions) may
cause adrenal insufficiency during pregnancy [19,20]. The majority of
published case reports describe pregnancy and/or delivery in women
with MPS I [3,4,6,7,9,21–23]. In several of these cases, pregnancy and
delivery was successful [6,7,9,10,22]. One report described the case of
a woman with MPS IH who had a successful bone marrow transplanta-
tion at 14 months of age [3]. Pregnancy was terminated at 9 weeks due
to concerns about the patient's health andher ability to care for the baby
[3]. Another report described rapid clinical deterioration of a woman
with MPS I after discontinuation of ERT during pregnancy and delivery
at 29 weeks of gestation of a baby of 1.25 kg [4]. Problems achieving ad-
equate combined spinal-epidural anesthesia and the need for emergen-
cy tracheostomy during planned cesarean section has been reported for
a 23-year-old woman with MPS IHS who had received ERT for over
10 years [21]. A 37-year-old woman with MPS IS receiving ERT devel-
oped signs of pre-eclampsia with hypertension and albuminuria at the
end of pregnancy and significant aggravation of preexisting valve dis-
ease after delivery [23]. Two case reports discussed pregnancy/delivery
inwomenwithMPS IVA. One of thewomen developed polyhydramnios
and dyspnea in the 21st week of gestation and delivered a premature
baby of 1.18 kg at 28 weeks [2]. The other case report concerned inade-
quate pain management during epidural anesthesia for cesarean sec-
tion, probably due to a combination of kyphoscoliosis, lumbar canal
stenosis, and thecal sac compression [8]. Only one published case report
discussed pregnancy and delivery in a woman with MPS VI [5]. She de-
veloped severe myelopathy in the third trimester of pregnancy due to
compression of the cervical spinal cord.
2. Methods
The case series presented here follows eight women and five men
with MPS and explores the pregnancy issues associated with their dis-
ease. The cases were presented at an advisory board meeting onTable 1
Demographics and clinical characteristics of the mothers and fathers with MPS.
Case MPS type Number of children Age at pregnancy/birth (males), y
MPS mothers
1 IHS 1 22
2 IVA 1 41
3 IVA 2 25
28
4 IVA 1 35
5 IVB 1 31
6 VI 1 21
7 VI 1 32
8 VI 3a 33
Mean (SD) 29.8 (6.5)
MPS fathers
9b II 1 27
10c II 1 24
11 IVA 1 30
12 IVA 1 31
13 IVA 3 41, 43, 45
Mean (SD) 34.4 (8.4)
NA: not available; M: male; F: female.
a Only third child (first child after diagnosis of MPS VI) is discussed.
b Died at age 28.
c Expecting a second child.pregnancy and fertility in MPS patients held April 18th, 2015 in Berlin,
Germany, and attended by international MPS experts.
3. Case reports
3.1. Demographics and clinical characteristics (Table 1)
Eight women and five men with MPS were followed at six tertiary
care centers in the US, UK, France, Austria, and Germany. The 13 cases
involved MPS IHS, MPS II, MPS IV (Morquio syndrome) A and B, and
MPSVI (Maroteaux-Lamy syndrome). Each patient depicted in this pub-
lication provided written informed consent. The men with MPS II were
brothers. Althoughmost of these patients had attenuated phenotypes of
MPS they all showed clearmanifestations of the disease, includingmus-
culoskeletal, respiratory, cardiac, and/or neurological problems. Two
patients showed severe short stature, below 125 cm (Table 1). None
had psychological or intellectual regression. One of the men with MPS
II (case 9) died at 28 years of age, 6 months after undergoing a lung
transplantation and less than 2 years after his son was born.
3.2. MPS mothers
Mean age at pregnancy of the eight women was 29.8 (SD 6.5) years
(Table 1). Six women had one child. Case 3 (MPS IVA) delivered two
children during the observed time interval. Case 8 has three children,
of which two were born before MPS VI was diagnosed; only her third
pregnancy is reported here. Case 2 (MPS IVA) had a miscarriage and
an extra-uterine pregnancy followed by right salpingectomy in the
year before the pregnancy. None of the other women had previous
pregnancies. None of the partners had MPS.
Fig. 1 provides details on the clinical history and pregnancy outcome
of cases 5 and 8. The Appendix provides an overview of all other female
cases discussed.
3.2.1. Complications during pregnancy
Complications during pregnancy included lumbar pain (case 6) and
migraine (cases 2 and 6) requiring paracetamol use, gastric pain and re-
flux requiring treatment with omeprazole (case 2), high relative weight
gain (18–24% for cases 3, 4, and 5), frequent spotting at 18 weeks (casers Height, cm Weight, kg
ERT/HSCT
Throughout pregnancy During lactation
148 NA ERT –
142 73 ERT –
147 41 – –
– –
114 35 – –
147 45 – –
149 75 ERT –
NA NA – –
146 39 ERT ERT
141.9 (12.5) 51.3 (17.9)
At conception
170 51 HSCT (age 17)
168 77 ERT
122 NA –
155 NA –
150 85 –
153.0 (19.3) 71.0 (17.8)
Clinical history
Thoracic deformity, weak legs, recurrent 
bronchitis at 3.5yrs 
Correction of leg axis bilat. in childhood  
Bilateral carpal tunnel surgery at 27 yrs 
Bilateral hip endoprosthesis at 28/29 yrs 
Bilateral hallux valgus correction
Menarche at 16-17 yrs
Complications during/after  pregnancy
High relative weight gain (23%) 
Delivery complicated by the large size of the child: ruptured 
uterus?, blood loss requiring blood transfusion 
Baby had breathing problems; neonatal intensive care for 5 days
MPS IVB: case 5
Fig. 1. Details on clinical history and pregnancy outcome of cases 5 and 8.
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adjustment due to hypotension at 23 weeks (case 7). Case 8 had pre-
existing primary hypothyroidism for which she received thyroxin sub-
stitution therapy; hyperemesis gravidarum during pregnancy resulted
in sub-optimal absorption of thyroxin and intermittent hypothyroidism.
Most women stopped working early during pregnancy. The husband of
case 4 lost his job because he had to assist his wifemost of the time dur-
ing her pregnancy.
3.2.2. Complications during delivery
Deliveries were between 34 and 40 weeks of gestation (Table 2).
Twowomen (cases 2 and 6) had uncomplicated, full-term, spontaneous
vaginal deliveries. Seven deliveries (in six women)were planned cesar-
ean sections. In six cases (1, 3 [2 deliveries], 4, 5, 8), this was due to ma-
ternal short stature with normal sized babies, leading to cephalopelvic
disproportion. Case 5 had blood loss requiring transfusion at delivery
with cesarean section atweek 37 of gestation. Because of the dispropor-
tion of the gravid uterus and the size of the abdomen, the uterine fundus
was below the rib cage. After opening of the uterus during cesarean sec-
tion, the child's head could not be extracted because it was not possible
to exert pressure away from the fundus. After several unsuccessful at-
tempts, the child was eventually removed with forceps and born in
the cephalic presentation. In the wake of these problems, the uterus
began to bleed. In case 7, pre-term delivery at week 37 was required
due to maternal aortic stenosis, atrial tachycardia, and a history of noc-
turnal seizures. Cesarean section was required due to a contracted ma-
ternal pelvis and transverse lie of the child. The mode of anesthesiaduring cesarean section was reported for five cases and included spinal
(cases 1 and 7), epidural (cases 5 and 8), and general anesthesia with
endotracheal intubation (case 3). No details about the techniques used
to perform spinal or epidural anesthesia are available. However, several
physicians indicated that the anesthesiologists were well prepared to
prevent ormanage any complications thatmayhave arisen during anes-
thesia, due to previous experiencewith the patient and/or availability of
relevant clinical information.
3.2.3. Maternal complications post delivery
Two women had complications after delivery. Case 4 had mastitis
and a breast abscess requiring emergency surgery and an umbilical her-
nia requiring surgical repair. She also had difficulties carrying the child
due to her short stature and required special equipment including a
baby crib designed for small parents. Case 8 had valve disease before
pregnancy for many years without deterioration, but deteriorated sig-
nificantly after delivery; she will require mitral valve replacement in
the near future. At least six women started breastfeeding after delivery
(Table 2). Three of the mothers discontinued after several days due to
insufficient milk production. Case 3 (MPS IVA), who had two children,
had lactation difficulties thatwere considered by themother to be relat-
ed to the small sizes of the babies (2.5 and 2.89 kg). The same problem
may apply to case 8 (MPS VI), who had a baby below the 3rd percentile.
The reason for the short lactation period in case 2 (MPS VIA) is not clear.
Case 5 (MPS IVB) continued lactation for 9 months and reported no
problems. Based on this information, we cannot conclude that insuffi-
cient milk production is MPS-related.
3.2.4. Neonatal complications
The baby in case 4, who was delivered at 34 weeks of gestation due
to the extremematernal short stature (114 cm), required supplemental
oxygen and a feeding tube and 4 weeks of neonatal intensive care. Five
days of neonatal intensive care was required for the baby in case 5 due
to breathing problems. In case 8, the child had hypoglycemia (glucose
30 mg/dL, which was likely due to the small size [44 cm] of the baby
and not related to the mother's MPS), a small ventricular septal defect
resulting in a left-right shunt, and an open foramen ovale, but devel-
oped normally afterwards, with normal cardiac function.
3.2.5. ERT use during pregnancy
ERT involves intravenous infusion of recombinant enzyme to com-
pensate for enzymedeficiencies inMPS patients. The therapy is current-
ly available forMPS I, II, IVA and VI [1,24]. Fourwomen (cases 1, 2, 6 and
8) continued ERT throughout pregnancy (Table 1) to ameliorate symp-
toms such as joint pain, chronic migraine, asthenia, and reduced endur-
ance that improved after they started ERT (Table 1). No adverse effects
of ERT on pregnancywere reported in any of these cases. Case 8 had ERT
infusions during lactation (4 weeks), but avoided breastfeeding in the
24-h period after infusion due to concerns that the enzyme concentra-
tion in the milk might increase. The reason why two of the mothers
with MPS IVA did not receive ERT during pregnancy is that ERT was
not yet available for this indication at the time of pregnancy. Currently,
no ERT is available for MPS IVB.
3.3. MPS fathers
The five men with MPS in the case series had a mean age of
30.6 years when their first child was born (Table 1). All had healthy
partners. The men with MPS IVA did not receive genetic counseling.
One man with MPS II (case 9) had successful HSCT at 17 years of age,
but developed pulmonary graft-versus-host disease after 2 months.
His brother was treated with ERT at the time of the pregnancy. All preg-
nancies and deliveries were uncomplicated. The partners of all three
men with MPS IVA had a previous miscarriage at 6 weeks or at the
end of the first trimester (case 13) of other pregnancies. All children
were healthy, with normal growth and development. Case 13 had
Table 2
Pregnancy, delivery and breastfeeding in mothers with MPS.
Case MPS type
Delivery, weeks
of gestation Mode of delivery Sex baby Weight baby, kg Weight for age %ile Length baby, cm Length for age %ile APGAR Lactation
1 IHS 37 Planned CS Male 2.60 5–10th 46 5th 9/9/10 No
2 IVA 40 Vaginal Male 3.33 25–50th 53 90th 9/10/10 4 days
3 IVA 37 Planned CS Female 2.50 5th 46 10th 7/8/9 Short time
38 Planned CS Female 2.89 10–25th 48 25th 8/9/10 Short time
4 IVA 34 Planned CS Female 1.95 b3rd 43 b3rd NA NA
5 IVB 37 Planned CS Male 3.29 25–50th 51 50–75th 7/9/10 9 months
6 VI 40 Vaginal Female 3.36 50th 51.5 75th 10/10/10 NA
7 VI 37 Planned CS Female 2.37 b3rd NA NA 7/8 yes
8 VI 38 Planned CS Male 2.27 b3rd 44 b3rd 9/10/10 4 weeks
Mean (SD) 37.6 (1.8) 2.73 (0.51) 47.8 (3.7)
CS: Cesarean section; NA: not available.
Centers for Disease Control and Prevention (CDC) weight and length for age percentiles (%iles) were derived from https://www.cdc.gov/growthcharts/html_charts/wtageinf.htm and
https://www.cdc.gov/growthcharts/html_charts/lenageinf.htm.
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the time of data collection.
4. Discussion
Despite the increasing number of MPS patients reaching adulthood,
reports on pregnancy remain relatively uncommon. The medical center
in France involved in this study had 75 adult MPS patients (≥18 years),
including 30 women with MPS I (N = 20), IV (N = 8) and VI (N = 2)
and 45 men with MPS I (N = 10), II (N = 22), IV (N = 7) and VI
(N = 6). Of these, only two women, with MPS IV and VI, and two men
with MPS II had children. One woman with MPS I had an elective abor-
tion at 18 years of age.
Several explanations may account for the relatively low number of
pregnancies in MPS patients. These patients may have an increased
risk of infertility, but this has not been sufficiently studied. In addition,
MPS can severely impact an individual's ability to lead an autonomous
lifestyle. Many patients require long-term care or find it necessary to
live at home which can hinder development of social or intimate rela-
tionships. Female patients must be willing to assume the risks associat-
ed with pregnancy and delivery, be able to care for their child and
overcome the financial demands related to pregnancy. For example,
most women in this case series stopped working during pregnancy
and, in one case, the patient's partner lost his job. Consequently, the
support of close friends, relatives or family members is critical. Patients
may also refrain from having children because they are apprehensive
about the risk of passing on the disease to their offspring (which is
low if their partner is unaffected). Finally, because of the shortened
life span of MPS patients, potential parents may fear leaving their chil-
dren motherless or fatherless at a young age. Relevant to this point,
one of the MPS II fathers in this case series died less than 2 years after
his son was born.
The fear of a difficult pregnancy and delivery for womenwithMPS is
not unfounded as demonstrated by the high incidence of complications
in this case series and in previous case reports [2–5], although many of
the milder complications, such as lumbar pain, migraine, reflux and
spotting, are common in pregnancy and may not be related to MPS.
Complications during pregnancy can arise from exacerbation of existing
clinical manifestations of MPS such as joint pain, cardiac, pulmonary or
gastrointestinal disease. The major MPS manifestations that can com-
promise life are mainly cardiac and respiratory (often due to short stat-
ure). Permanent post-delivery worsening of clinical manifestations
occurred in onewomanwithin our case series, indicating that pregnan-
cy may have a permanent impact on the mother's health. Despite the
many issues the cases encountered during pregnancy and delivery,
most children were born healthy, although some neonatal care was
required.
MPS patients have significant anesthetic risk secondary to their un-
derlying disease and surgeries require significant planning [25].Therefore, most physicians preferred a scheduled cesarean section
under epidural or spinal anesthesia to a natural delivery (which could
require an emergency cesarean section with a higher likelihood of gen-
eral anesthesia and increased risk). This could partly explain why our
cases did not reportmany respiratory complications. Although no prob-
lemswith local anesthesia were reported, a recently publishedMPS IVA
case suggested that a combination of kyphoscoliosis, lumbar canal ste-
nosis and cord compression can lead to sub-optimal distribution of epi-
dural anesthetics [8].
Four cases received ERT during pregnancy and no apparent ERT-re-
lated adverse effects were reported. More research is needed, however,
to assess whether ERT may improve the outcome of pregnancy and to
determine the potential benefits and risks of ERT during lactation
(only one case received infusions during a very short lactation period).
A recently published case report showed uneventful pregnancy and de-
livery in awomanwithMPS I receiving ERT [7]. No recombinant enzyme
was detected in breast milk [7]. Several patient registries are collecting
information on pregnancy and lactation in patients with MPS I, IVA
and VI. The decision to start or continue ERT during pregnancy should
take into account the safety category listed on the US and EU ERT labels,
as well as the risks of exacerbation of disease associated with cessation
of ERT.
5. Conclusions
The present case series demonstrates that women with MPS have
high-risk pregnancies and deliveries secondary to their underlying dis-
ease. Nevertheless, despite complications during pregnancies, with ap-
propriate pre-conceptual multi-disciplinary evaluation, optimization
and discussion regarding potential risks, combined with regular multi-
disciplinary maternal and fetal surveillance in a tertiary center, the out-
come of most pregnancies in this case series was favorable with all
babies developingnormally. Fertility, pregnancy andparenthood should
be discussed regularly with women andmenwithMPS so that the risks
are understood and pregnancies can be planned tominimize these risks.
Patients should also be aware of the support that is available, including
that from MPS patient organizations, and the need for thorough pre-
conceptual evaluation by a multi-disciplinary team of health care pro-
fessionals including MPS specialists.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ymgmr.2016.08.002.
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